Cytochromes P450, vascular tone varicosis;Revue les cytochromes P450, le tonus vasculaire et la pathologie variqueuse

Annales Pharmaceutiques Francaises

Volumn 61, Issue 4, 2003, Pages 234-242

  Bertrand, C ^a   Batt, A M ^a  

^a Centre du Medicament URA CNRS 597   (France)

Author keywords

Arachidonic acid metabolism; Cytochromes P450; Vascular tone; Venous pathology

Indexed keywords

ARACHIDONIC ACID; CYTOCHROME P450; CYTOCHROME P450 3A5; CYTOKINE;

AGE; BLOOD VESSEL WALL; CELL INFILTRATION; CHRONIC VEIN INSUFFICIENCY; CLINICAL FEATURE; DNA POLYMORPHISM; ENDOTHELIUM LESION; HORMONE ACTION; HUMAN; HYPERTENSION; HYPOXIA; LEUKOCYTE; LIFESTYLE; MULTIPARA; MUSCLE HYPERTROPHY; MYOSITIS; NONHUMAN; REVIEW; RISK FACTOR; SHEAR STRESS; SMOOTH MUSCLE FIBER; SYMPTOM; THERMAL EXPOSURE; VARICOSIS; VEIN TONE; VENOUS PRESSURE; ANIMAL; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; METABOLISM; PATHOLOGY; VEIN INSUFFICIENCY;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; POLYMORPHISM, GENETIC; VENOUS INSUFFICIENCY;

EID: 0038376550     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Michiels C, Bouaziz N, Remacle J. Role of the endothelium and blood stasis in the appearance of varicose veins. Int Angiol 2002; 21: 1-8.
2. Boegehold MA. Heterogeneity of endothelial function within the circulation. Curr Opin Nephrol Hypertens 1998; 7: 71-8.
3. Michiels C, Arnould T, Remacle J. Endothelial cell responses to hypoxia: initiation of a cascade of cellular interactions. Biochem Biophys Acta 2000; 1497: 1-10.
4. Korenaga R, Ando J, Kosaki K, Isshiki M, Takada Y, Kamiya A. Negative transcriptional regulation of the VCAM-1 gene by fluid shear stress in murine endothelial cells. Am J Physiol 1997; 273: C1506-15.
5. Resnick N, Collins T, Atkinson W, Bonthron DT, Dewey CF, Gimbron MA. Platelet - derived growth factor b chain promoter contains a cis-actin fluid shear stress-responsive element. Proc Nat Acad Sci USA 1993; 90: 7908.
6. London NJM, Nash R. ABC of arterial and venous disease, Varicose veins. BMJ 2000; 320: 1391-4.
7. Mashiah A, Berman V, Thole HH, Rose SS, Pasik S, Schwarz H et al. Estrogen and progesterone receptors in normal and varicose saphenous veins. Cardiovasc Surg 1999; 7: 327-31.
8. Schaub FJ, Han DK, Liles WC et al. Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells. Nat Med 2000; 6: 790-6.
9. Beasley D, McGuiggin ME, Dinarello CA. Human vascular smooth muscle cells produce an intracellular form of interleukin-1 receptor antagonist. Am J Physiol 1995; 269: C961-8.
10. Capdevila JH, Falck JR, Harris RC. Cytochrome P450 and arachidonic acid bioactivation: molecular and functionnal properties of the arachidonate monooxygenase. J Lipid Res 2000; 41: 163-81.
11. Rifkind AB, Lee C, Chang TKH, Waxman D. Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1 and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes. Arch Biochim Biophys 1995; 320: 380-9.
12. Powell PK, Wolf I, Jin R, Lasker JM. Metabolism of arachidonic acid to 20-hydroxy-5,8,11,14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11. J Pharmacol Exp Ther 1998; 285: 1327-36.
13. Minamiyama Y, Takemura S, Akiyama T, Imaoka S, Inoue M, Funae Y et al. Isoforms of cytochrome P450 on organic nitrate-derived nitric oxide release in human heart vessels. FEBS Lett 1999; 452: 165-9.
14. Hukkanen J, Hakkola J, Anttila S, Piipari R, Karjalainen A, Pelkonen O et al. Detection of mRNA encoding xenobiotic-metabolizing cytochrome P450s in human bronchoalveolar macrophages and peripheral blood lymphocytes. Mol Carcinog 1997; 20: 224-30.
15. Mace K, Bowman ED, Vautravers P, Shields PG, Harris CC, Pfeifer AM. Characterisation of xenobiotic-metabolising enzyme expression in human bronchial mucosa and peripheral lung tissues. Eur J Cancer 1998; 34: 914-20.
16. Fisslthaler B, Popp R, Michaelis UR, Kiss L, Fleming I, Busse R. Cyclic stretch enhances the expression and activity of coronary endothelium-derived hyperpolarizing factor synthase. Hypertension 2001; 38: 1427-32.
17. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 1999; 401: 493-7.
18. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999; 285: 1276-9.
19. Lasker JM, Chen WB, Wolf I, Bloswick BP, Wilson PD, Powell PK. Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11. J Biol Chem 2000; 275: 4118-26.
20. Zeldin DC, Foley J, Ma J, Boyle JE, Pascual JM, Moomaw CR et al. CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance. Mol Pharmacol 1996; 50: 1111-7.
21. Yang B, Graham L, Dikalov S, Mason RP, Falck JR, Liao JK et al. Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. Mol Pharmacol 2001; 60: 310-20.
22. Scarborough PE, Ma J, Qu W, Zeldin DC. P450 subfamily CYP2J and their role in the bioactivation of arachidonic acid in extrahepatic tissues. Drug Metab Rev 1999; 31: 205-34.
23. Raunio H, Hakkola J, Hukkanen J, Pelkonen O, Edwards R, Boobis A et al. Expression of xenobiotic-metabolizing cytochrome P450s in human pulmonary tissues. Arch Toxicol Suppl 1998; 20: 465-9.
24. Celander MC, Moore MJ, Stegeman JJ. Cellular localization of CYP3A proteins in various tissues from pilot whale (Globicephala melas). Environ Toxicol Pharmacol 2000; 8: 245-53.
25. Farin FM, Pohlman TH, Omiecinski CJ. Expression of cytochrome P450s and microsomal epoxide hydrolase in primary cultures of human umbilical vein endothelial cells. Toxicol Appl Pharmacol 1994; 124: 1-9.
26. Hoebel BG, Steyrer E, Graier WF. Origin and function of epoxyeicosatrienoic acids in vascular endothelial cells: more than just endothelium-derived hyperpolarizing factor? Clin Exp Pharmacol Physiol 1998; 25: 826-30.
27. Zhao W, Parrish AR, Ramos KS. Constitutive and inducible expression of cytochrome P450IA1 and P450IB1 in human vascular endothelial and smooth muscle cells. In Vitro Cell Dev Biol Anim 1998; 34: 671-3.
28. Rochat B, Morsman JM, Murray GI, Figg WD, McLeod HL. Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther 2001; 296: 537-41.
29. Tang YM, Green BL, Chen GF et al. Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics 2000; 10: 761-6.
30. Kristensen VN, Borresen-Dale AL. Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism. Mutat Res 2000; 462: 323-33.
31. Laethem RM, Balazy M, Falck JR, Laethem CL, Koop DR. Formation of 19 (S)-, 19 (R)-, and 18 (R)-hydroxyeicosatetraenoic acids by alcohol-inducible cytochrome P450 2E1. J Biol Chem 1993; 268: 12912-8.
32. Stoilov I, Akarsu AN, Alozie I, Child A, Barsoum-Homsy M, Turacli ME et al. Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am J Hum Genet 1998; 62: 573-84.
33. Shimada T, Watanabe J, Inoue K, Guengerich FP, Gillam EM. Specificity of 17beta-oestradiol and benzo[a]pyrene oxidation by polymorphic human cytochrome P4501BI variants substituted at residues 48, 119 and 432. Xenobiotica 2001; 31: 163-76.
34. Ibeanu GC, Blaisdell J, Ferguson RJ, Ghanayem BI, Brosen K, Benhamou S et al. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther 1999; 290: 635-40.
35. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6: 341-9.
36. Persson I, Johansson I, Bergling H et al. Genetic polymorphism of cytochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer. FEBS Lett 1993; 319: 207-11.
37. Hu Y, Oscarson M, Johansson I et al. Genetic polymorphism of human CYP2E1: characterization of two variant alleles. Mol Pharmacol 1997; 51: 370-6.
38. King ML, Ma J, Srettabunjong S et al. Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol Pharmacol 2002; 61: 840-52.
39. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-91.
40. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11: 773-9.
41. Morgan ET. Regulation of cytochrome P450 by inflammatory mediators why and how? Drug Metab Dispos 2001; 29: 207-12.
42. Kessler P, Popp R, Busse R, Schini-Kerth VB. Proinflammatory mediators chronically downregulate the formation of the endothelium-derived hyperpolarizing factor in arteries via a nitric oxide/cyclic GMP-dependent mechanism. Circulation 1999; 99: 1878-84.
43. Beurton F, Gueret G, Horisberger M, Cheron G, Cresteil T. Transcriptional activation of CYP2C, MxA and Fas in suddent infant death syndrome. Int J Mol Med 1999; 3: 33-9.
44. Zhu D, Birks EK, Dawson CA, Patel M, Falck JR, Presberg K et al. Hypoxic pulmonary vasoconstriction is modified by P-450 metabolites. Am J Physiol Heart Circ Physiol 2000; 279: H1526-33.
45. Bylund J, Kunz T, Valmsen K, Oliw EH. Cytochromes P450 with bisallylic hydroxylation activity on arachidonic and linoleic acids studied with human recombinant enzymes and with human and rat liver microsomes. J Pharmacol Exp Ther 1998; 284: 51-60.
46. Okahara K, Sun B, Kambayashi J. Upregulation of prostacyclin synthesis-related gene expression by shear stress in vascular endothelial cells. Arterioscler Thromb Vasc Biol 1998; 18: 1922-6.
47. Fisslthaler B, Hinsch N, Chataigneau T, Popp R, Kiss L, Busse R et al. Nifedipine increases cytochrome P4502C expression and endothelium-derived hyperpolarizing factor-mediated responses in coronary arteries. Hypertension 2000; 36: 270-5.
48. Badier-Commander C, Couvelard A, Henin D, Verbeuren T, Michel JB, Jacob MP. Smooth muscle cell modulation and cytokine overproduction in varicose veins. An in situ study. J Pathol 2001; 193: 398-407.
49. Kockx MM, Knaapen MW, Bortier HE, Cromheeke KM, Boutherin-Falson O, Finet M. Vascular remodeling in varicose veins. Angiology 1998; 49: 871-7.
50. Hodek P, Trefil P, Stiborova M. Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem Biol Interact 2002; 139: 1-21.